A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Of K0706 In Subjects With Early Parkinson's Disease

Clinical Trial Details

The purpose of this double-blinded study is to find out about the ability of K0706, the study drug, to slow the progression of Parkinson's disease, as well as the safety of K0706. K0706 is intended to work by blocking a substance in the body called "Abl". Abl is a kind of Tyrosine Kinase Inhibitor. There is evidence from animal models that overactivation of Abl may play a role in Parkinson's disease, and that reducing this activity may help slow the progression of disease.

There are currently no medications proven to slow progression of Parkinson's disease.

About 10 people (at this site) will take part in this 44 week long study. There will be a total of 11 visits, not including the Screening Visit, after which patients will be randomized to receive placebo or the study drug at either 96 mg or 192 mg. Notably, the changes from baseline to Week 40 in several motor scales will be analyzed as a primary measure of efficacy.

Key Eligibility:

Age 50+
Willingness to participate for the 44 week study period
Within three years of a Parkinson's disease diagnosis
Naïve to Dopaminergic agents within 9 months of first visit
Detailed eligibility will be reviewed when you contact the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Maissa Trabilsy
(212) 746-6575
mnt4001@med.cornell.edu

Primary Investigator(s)

Harini Sarva, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

1904020267

ClinicalTrials.gov:

NCT03655236

Status

Open to Enrollment

Age Group

Adult

Disease

Parkinson's Disease